Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	-	-	-	-	0.2
Cost of Revenue	-	-	-	-	0.08
Gross Profit	-	-	-	-	0.12
Selling, General & Admin	7.17	6.68	8.28	6.58	6.66
Research & Development	9.51	4.59	9.93	5.56	4.17
Operating Expenses	16.68	11.28	18.21	12.14	10.84
Operating Income	-16.68	-11.28	-18.21	-12.14	-10.72
Interest Expense	-	-	-	-	-0.26
Interest & Investment Income	0.71	0.91	0.25	0.08	0.11
Currency Exchange Gain (Loss)	-0.02	-0.02	-0.07	-0.3	-0.68
Other Non Operating Income (Expenses)	3.22	-2.73	0.01	5.34	-2.43
EBT Excluding Unusual Items	-12.77	-13.11	-18.02	-7.02	-13.98
Merger & Restructuring Charges	-	-1.49	-33.51	-3.2	-
Asset Writedown	-0	-0.09	-0.44	-0.25	-5.7
Pretax Income	-12.77	-14.69	-51.97	-10.47	-19.68
Income Tax Expense	-3.2	-1.83	-9.54	-0.65	-
Net Income	-9.57	-12.85	-42.43	-9.82	-19.68
Net Income to Common	-9.57	-12.85	-42.43	-9.82	-19.68
Shares Outstanding (Basic)	12	10	7	6	2
Shares Outstanding (Diluted)	12	10	7	6	2
Shares Change (YoY)	26.85%	28.16%	21.09%	148.46%	40.25%
EPS (Basic)	-0.79	-1.35	-5.71	-1.60	-7.96
EPS (Diluted)	-0.79	-1.35	-5.71	-1.60	-7.96
Free Cash Flow	-14.9	-12.36	-15.93	-17.23	-14.39
Free Cash Flow Per Share	-1.23	-1.30	-2.14	-2.81	-5.82
Gross Margin	-	-	-	-	61.22%
Operating Margin	-	-	-	-	-5467.35%
Profit Margin	-	-	-	-	-10039.80%
Free Cash Flow Margin	-	-	-	-	-7340.82%
EBITDA	-16.67	-11.27	-18.08	-11.22	-9.79
D&A For EBITDA	0.01	0.01	0.12	0.92	0.92
EBIT	-16.68	-11.28	-18.21	-12.14	-10.72

Updated Jun 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q